Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.70%
#2 Ontology Gas Ontology Gas +17.76%
#3 GoPlus Security GoPlus Security +9.80%
#4 Janction Janction +9.64%
#5 DMT-NAT DMT-NAT +7.80%
#6 Provenance Blockchain Provenance Blockchain +6.63%
#7 B3 (Base) B3 (Base) +6.09%
#8 Ontology Ontology +6.08%
#9 Status Status +5.87%
#10 Everything Everything +5.64%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Rangering i aksjer #33997
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Aksjekurs
$0.1502
Sist synkronisert: 2024-11-04
Markedsverdi
$6.43M
Endring (1 dag)
-5.45%
Endring (1 år)
0.00%
Land
US
Handel Renalytix Plc (RNLX)

Kategori

Healthcare
P/B-forhold for Renalytix Plc (RNLX)
P/B-forhold per August 2026 TTM: -1.43
Ifølge Renalytix Plc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) -1.43. Ved slutten av 2023 hadde selskapet et P/B-forhold på 6.50.
P/B-historikk for Renalytix Plc fra 2018 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
2026 (TTM) -1.43 -17.55%
2024 -1.73 -126.57%
2023 6.50 237.16%
2022 1.93 -83.22%
2021 11.50 5.79%
2020 10.87 6.56%
2019 10.20 -100.03%
2018 -30.05K 0.00%
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
 3.0416 -313.25%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
 48.0487 -3,468.77%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
 6.2063 -535.13%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
 21.0676 -1,577.08%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
 - -
US